SecBot SecBot
8-K ·Filed Jul 7, 2026

SABS

SAB Biotherapeutics, Inc.
BULLISH
Impact 4/10
Horizonmonths Processed4mo ago SEC0001193125-26-296936
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The grant provides external validation and modest non-dilutive funding for an expanded clinical program. The key catalyst remains the Phase 2b SAFEGUARD data readout. Monitor enrollment updates and any future data releases from PRISE-hATG.

DirectionBullish
Confidencehigh
Horizonmonths

SAB-142

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2b (registrational)
Time to market
Potentially 2028-2029 if Phase 2b succeeds, given the registrational trial topline reads out in 2H 2027 and accelerated approval is possible via the C-peptide surrogate endpoint pathway
Next catalyst
None dated

What to watchSAB-142 is early-stage but has strong institutional validation and ample cash runway through 2028. The next major catalyst (Phase 2b topline data) is still over a year away, so near-term moves will be driven by enrollment milestones, conference data presentations, and progress on the PRISE-hATG study. The stock carries elevated short interest (~56-61% short ratio), so positive enrollment updates could trigger short squeezes. For investors, this is a pre-revenue binary bet with no near-term FDA decision, sizing accordingly is key.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.90
T+0 close · Jul 7, 2026 · via day close
Latest settled
−18.72%
T+60 · $3.17
Vs SPY
−20.71%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 7 $3.90entry
  2. T+1 · 4mo ago −3.33%α −3.02% · $3.77
  3. T+5 · 4mo ago −7.69%α −8.24% · $3.60
  4. T+20 · 4mo ago −2.82%α −4.15% · $3.79
  5. T+60 · 7w ago −18.72%α −20.71% · $3.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 in Stage 3 type 1 diabetes patients 100 days to 2 years from diagnosis. The investigator-led study extends the clinical program beyond the typical 100-day window and complements the ongoing Phase 2b SAFEGUARD trial. SAB BIO will co-fund the study; the grant amount was not disclosed.

Key Facts

  • Breakthrough T1D awarded a grant to Dr. Michael Haller at University of Florida for the PRISE-hATG study of SAB-142.
  • PRISE-hATG evaluates SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis, extending beyond the typical 100-day window.
  • The study is randomized, double-blind, placebo-controlled and harmonized with the Phase 2b SAFEGUARD trial.
  • SAB BIO will co-fund the study; grant amount not disclosed.

Financial Impact

Grant amount undisclosed; SAB BIO co-funds the study. No revenue or earnings impact.

Risk Factors

  • Clinical trial risk, SAB-142 may fail to meet endpoints in PRISE-hATG or SAFEGUARD.
  • Competition from approved T1D therapies (e.g., teplizumab) and other pipeline candidates.
  • Cash burn, co-funding adds to expenses; additional financing may be needed.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-296936
Document: sabs-ex99_1.htm0001193125-26-296936
Document: 0001193125-26-296936-index-headers.html0001193125-26-296936
Document: 0001193125-26-296936-index.html0001193125-26-296936
Document: 0001193125-26-296936.txt0001193125-26-296936

Track record

15 reports on SABS

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
  4. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
  5. Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
  6. Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
  8. Jul 7, 202618w ago 8-K Bullish 4/10 Viewing Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
  9. May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
  10. May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 7, 2026